Reasons to Retain Veeva Systems Stock in Your Portfolio Now

Zacks09-25

Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2025 performance and strategic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470229639?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hb34T5JpqfOKFdxuauyatA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/560ce7090345bb7408c706b8e0a8c3fc","is_english":true,"pubTime":"2024-09-25 23:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2470229639","market":"us","top_or_hot":-1,"title":"Reasons to Retain Veeva Systems Stock in Your Portfolio Now","media":"Zacks","content":"<div>\n<p>Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2025 performance and strategic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-veeva-systems-stock-154300215.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reasons to Retain Veeva Systems Stock in Your Portfolio Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReasons to Retain Veeva Systems Stock in Your Portfolio Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-25 23:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/reasons-retain-veeva-systems-stock-154300215.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2025 performance and strategic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-veeva-systems-stock-154300215.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4185","symbol_name":"保健护理机构","start_time":0,"source_url":"https://finance.yahoo.com/news/reasons-retain-veeva-systems-stock-154300215.html","article_id":"2470229639","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hb34T5JpqfOKFdxuauyatA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/560ce7090345bb7408c706b8e0a8c3fc"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470229639","pubTimestamp":1727278980,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Veeva Systems Inc.VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2025 performance and strategic deals, is expected to contribute further. Stiff competition and rising operational costs persist.This Zacks Rank #3  company’s shares have gained 8% in the year-to-date period compared with 20.9% growth of theindustry.The S&P 500 Composite has risen 20.2% during the said time frame.The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $34.17 billion. The company projects 24.4% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.41%.Robust Product Portfolio:We are optimistic about Veeva Systems’ unique solutions, which include Veeva Vault, Veeva CRM , Veeva Network and Veeva OpenData.In June, the compa","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4185":"保健护理机构","BK4583":"猴痘概念","UHS":"Universal Health Services Inc Cl","BK4528":"SaaS概念","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","EDC":"新兴市场ETF-Direxion三倍做多","DGX":"奎斯特诊疗","BK4196":"保健护理服务","VEEV":"Veeva Systems Inc.","BK4167":"医疗保健技术","ABM":"反导工业公司","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4120":"环境与设施服务","BK4588":"碎股","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4504":"桥水持仓"},"translate_title":"现在将Veeva Systems股票保留在您的投资组合中的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VEEV":1,"UHS":1,"EDC":1,"ABM":1,"DGX":1},"content_text":"Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2025 performance and strategic deals, is expected to contribute further. Stiff competition and rising operational costs persist.\nThis Zacks Rank #3 (Hold) company’s shares have gained 8% in the year-to-date period compared with 20.9% growth of the industry. The S&P 500 Composite has risen 20.2% during the said time frame.\nThe renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $34.17 billion. The company projects 24.4% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.41%.\nImage Source: Zacks Investment Research\nReasons Favoring VEEV’s Growth\nStrong Q2 Results: Veeva Systems’ solid second-quarter fiscal 2025 results buoy optimism. The uptick in the overall top line and bottom line and robust performance by the Subscription services segment during the quarter were impressive. In the fiscal second quarter, Veeva Systems’ gross profit improved 20.1% to $505.8 million. The gross margin expanded 340 basis points (bps) to 74.8%.\nRobust Product Portfolio: We are optimistic about Veeva Systems’ unique solutions, which include Veeva Vault, Veeva CRM (customer relationship management), Veeva Network and Veeva OpenData.\nVeeva Systems continues to expand its product portfolio with new launches. In August, the company reached a significant milestone on its path to connect sales, marketing, medical, and service to enable true customer centricity with the release of Vault CRM Service Center.\nVeeva Systems also added 14 new Vault CRM customers in the fiscal second quarter. The company also commented on the latest release of Veeva Site Connect, which is part of the Veeva Clinical Platform. Veeva Site Connect plays a critical role as the industry moves to simplify and standardize site collaboration, and seven of the top 20 biopharmas have already adopted Veeva Site Connect to streamline trials.\nAlso, in clinical, Veeva Clinical Database (CDB), a significant innovation in clinical data, has been selected by seven top 20 biopharmas to reduce manual query work and increase speed and efficiency in trials.\nStrategic Deals: We are upbeat about Veeva Systems’ recent few collaborations. In June, the company announced a partnership with Vita Global Sciences that is likely to help the latter improve its clinical data management processes, as well as collaborations with key trial stakeholders. The latest adoption of Veeva Vault electronic data capture (EDC), part of the Veeva Clinical Platform, is likely to provide a boost to the Veeva Development Cloud business.\nIn June, the company also declared that Hangzhou Tigermed Consulting Co., Ltd. had selected Veeva Vault EDC as its technology foundation for modern EDC.\nFactors That May Offset the Gains for VEEV\nStiff Competition:  Veeva Systems operates in a highly competitive market. In new sales cycles within the company’s largest product categories, it competes with other cloud-based solutions from providers that make applications geared toward the life sciences industry, like IQVIA Inc. The company’s Commercial Cloud and Veeva Vault application suites also compete to replace client server-based legacy solutions offered by companies such as Oracle, Microsoft Corporation, and other smaller application providers.\nRising Costs: VEEV has been incurring huge operating expenses in recent months. Sales and marketing expenses for the second quarter of fiscal 2025 increased 4.7% year over year. Management anticipates a further increase in these expenses throughout fiscal 2025. This is mainly due to employee-related costs as the company expands its workforce to bolster sales and marketing efforts for its product offerings and to continue growing its sales capacity across all solutions. In the fiscal second quarter, the total operating expenses increased 6.9% year over year. \nEstimate Trend\nVeeva Systems is witnessing a stable estimate revision trend for fiscal 2025. In the past 30 days, the Zacks Consensus Estimate for earnings has moved north to $6.23 per share.\nThe Zacks Consensus Estimate for third-quarter fiscal 2025 revenues is pegged at $683.7 million, indicating a 10.9% improvement from the year-ago quarter’s reported number.\nKey Picks\nSome better-ranked stocks in the broader medical space are Universal Health Service UHS, Quest Diagnostics DGX and ABM Industries ABM. While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nUniversal Health Service has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.\nUniversal Health Service has gained 56.1% compared with the industry's 48.1% rise so far this year.\nQuest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.\nQuest Diagnostics shares have gained 13.9% so far this year compared with the industry’s 17.9% rise.\nABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.\nABM's shares have risen 27.4% so far this year compared with the industry’s 17% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nUniversal Health Services, Inc. (UHS) : Free Stock Analysis Report\nABM Industries Incorporated (ABM) : Free Stock Analysis Report\nVeeva Systems Inc. (VEEV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470229639"}